Animal models in the development of symptomatic and preventive drug therapies for Alzheimer's disease

Annals of Medicine

Volumn 30, Issue 6, 1998, Pages 566-576

  Riekkinen Jr , Paavo ^a   Schmidt, Bernard H ^b   Van Der Staay, F Josef ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b BAYER AG   (Germany)

Author keywords

Alzheimer's disease; Amyloid precursor protein gene (APP); Animal model; Drug administration schedules; Learning; Memory; Rat; Transgenic mouse; Validity

Indexed keywords

NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BRAIN FUNCTION; COGNITION; GENE MUTATION; GENETIC ENGINEERING; HUMAN; INTELLECT; MEMORY; NONHUMAN; PATHOPHYSIOLOGY; PHENOMENOLOGY; PRIORITY JOURNAL; THINKING; TRANSGENIC ANIMAL;

EID: 2442737838     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899809002606     Document Type: Article

References (56)

1. Butler RN. Population aging and health. BMJ 1997; 315: 1082-4.
2. Molnar FJ, Dalziel WB. The pharmacoeconomics of dementia therapy. Drugs Aging 1997; 19: 219-33.
3. American Psychiatric Association. DSM IV: Diagnostic and Statistical Manual of Mental Disorders IV. 4th edn. Washington, DC: APA Press; 1994.
4. Adams RD, Victor M, Ropper AH. Principles of Neurology. 6th edn. New York: McGraw-Hill; 1997.
5. van der Staay FJ. The Study of Behavioral Dysfunctions: an Evaluation of Selected Animal Models. Bochum, Germany: Ruhr-Universität; 1998.
6. D'Mello GD, Steckler T. Animal models in cognitive behavioural pharmacology: an overview. Brain Res Cogn Brain Res 1996; 3: 345-52.
7. Willner P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 677-90.
8. Willner P. Behavioural models in psychopharmacology. In: Willner P, ed. Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. Cambridge: Cambridge University Press; 1991.
9. McKinney WT, Bunney WE. Animal model of depression: I. Review of evidence: implications for research. Arch Gen Psychiatry 1969; 21: 240-8.
10. Nitsch RM. From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 1996; 5: 477-82.
11. Roses AD. The Alzheimer diseases. Curr Opin Neurobiol 1996; 6: 644-50.
12. Lienert GA. Testaufbau und Testanalyse. Weinheim, Germany: Verlag Julius Beltz; 1961.
13. Gamzu E. Animal behavioral models in the discovery of compounds to treat memory dysfunction. Ann N Y Acad Sci 1985; 444: 370-93.
14. Kaplan RM, Saccuzzo DP. Psychological testing. Principles, Applications, and Issues. 4th edn. Pacific Grove: Brooks/ Cole Publishing Company; 1997.
15. Runkel PJ, McGrath JE. Research on Human Behavior. A Systematic Guide to Method. New York: Holt, Rinehart and Winston; 1972.
16. McKinney WT. Animal models of depression: an overview. Psychiatr Dev 1984; 2: 77-96.
17. Barnes CA. Animal models of age-related cognitive decline. In: Boller F, Grafman J, eds. Handbook of Neuropsychology. Vol 4. Amsterdam: Elsevier; 1990: 169-96.
18. Gallagher M, Pelleymounter MA. Spatial learning deficits in old rats: a model for memory decline in the aged. Neurobiol Aging 1988; 9: 549-56.
19. Schuurman T, Traber J. Old rats as an animal model for senile dementia: behavioural effects of nimodipine. In: Bergener M, Reisberg B, eds. Diagnosis and Treatment of Senile Dementia. Berlin: Springer Verlag; 1989.
20. Markowska AJ, Ingram DK, Barnes CA, et al. Acetyl-1-carnitine 1: effects on mortality, pathology and sensory-motor performance in aging rats. Neurobiol Aging 1990; 11: 491-8.
21. 4-9 analog enhances social attention in aging rats: a longitudinal study. Neurobiol Aging 1991; 13: 153-8.
22. Elias PK, Elias MF. Effects of age on learning ability: contributions from the animal literature. Exp Aging Res 1976; 2: 165-86.
23. Miyamoto M, Kiyota Y, Yamazaki N, et al. Age-related changes in learning and memory in the senescence-accelerated mouse (SAM). Physiol Behav 1986; 38: 399-406.
24. Finch CE, Tanzi RE. Genetics of aging. Science 1997; 278: 407-11.
25. Ordy JM. Principles of mammalian aging. In: Ordy JM, Brizzee KR, eds. Advances in Behavioral Biology. New York: Plenum Press; 1975.
26. Russell ES. Genetic considerations in the selection of rodent species and strains for research in aging. In: Gibson DC, ed. Development of the Rodent as a Model System of Aging. Bethesda, MD; 1972.
27. Burek JD. Pathology of Aging Rats. West Palm Beach, FL: CRC Press; 1978.
28. Gleiser CA, Shain SA. The aging AXC/SSh rat: assessment of longevity and prevalence of neoplastic and nonneoplastic diseases in necropsied rats. J Gerontol 1986; 41: 590-8.
29. Masoro EJ. Mortality and growth characteristics of rat strains commonly used in aging research. Exp Aging Res 1980; 6: 219-33.
30. Baxter MG, Gallagher M. Neurobiological substrates of behavioral decline: models and data analytic strategies for individual differences in aging. Neurobiol Aging 1996; 17: 491-5.
31. Caprioli A, Markowska AL, Olton DS. Acetyl-L-carnitine: chronic treatment improves spatial acquisition in a new environment in aged rats. J Gerontol A Biol Sci Med Sci 1995; 50: B232-6.
32. Gallagher M, Burwell R, Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 1993; 107: 618-26.
33. 2-muscarinic receptor agonist in aged memory-impaired rats. J Neurosci 1995: 15; 1455-62.
34. Rasmussen T, Schliemann T, Sørensen JC, Zimmer J, West MJ. Memory impaired aged rats: no loss of principal hippocampal and subicular neurons. Neurobiol Aging 1996; 17: 143-7.
35. Ingram DK. Brain-behavior linkages in aged rodent models: strategies for examining individual differences. Neurobiol Aging 1996; 17: 497-9.
36. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749-60.
37. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457-9.
38. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90.
39. Davison AN. Pathophysiology of ageing brain. Gerontology 1987; 33: 129-35.
40. Jacobs RW, Butcher LL. Histopathology of the basal forebrain and its targets in Alzheimer dementia. In: Fisher A, Hanin I, Lachman C, eds. Alzheimer's and Parkinson's Diseases: Strategies for Research and Development. New York: Plenum Press; 1986.
41. Vogels OJM, Broere CAJ, ter Laak HJ, ten Donkelaar HJ, Nieuwenhuys R, Schulte BPMl. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol Aging 1990; 11: 3-13.
42. Decker MW. Animal models of cognitive function. Crit Rev Neurobiol 1995; 9: 321-43.
43. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I. Psychopharmacology 1992; 107: 144-59.
44. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II. Psychopharmacology 1992; 107: 461-73.
45. Wong PC, Zheng H, Chen H, et al. Presenilin 1 is required for Notch 1 DII1 expression in the paraxial mesoderm. Nature 1997; 387: 288-92.
46. Loring JF, Paszty C, Rose A, et al. Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. Neurobiol Aging 1996; 17: 173-82.
47. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, AB elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
48. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F b-amyloid precursor protein. Nature 1995; 373: 523-27.
49. Irizarry MC, Soriano F, McNamara M, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997; 17: 7053-9.
50. Moran PM, Higgins LS, Cordell B, Moser PC. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc Natl Acad Sci U S A 1995; 92: 5341-5.
51. Nalbantoglu J, TiradoSantiago G, Lahsaini A, et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 1997; 387: 500-5.
52. Yamaguchi F, Richards SJ, Beyreuther K, Salbaum M, Carlson GA, Dunnett SB. Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory. Neuroreport 1991; 2: 781-4.
53. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate AB1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17: 1005-13.
54. Citron M, Westaway D, Xia WM, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997; 3: 67-72.
55. Hardy J. The Alzheimer family of disease: many etiologies, one pathogenesis. Proc Natl Acad Sci U S A 1997; 94: 2095-7.
56. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998; 4: 97-100.